• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

当前和未来治疗 COVID-19 的方法。

Current and future therapeutical approaches for COVID-19.

机构信息

Henan Provincial Key Laboratory of Children's Genetics and Metabolic Diseases, Children's Hospital Affiliated to Zhengzhou University, Zhengzhou University, Zhengzhou 450001, China.

School of Pharmaceutical Science, Zhengzhou University, Zhengzhou, Henan 450001, China.

出版信息

Drug Discov Today. 2020 Aug;25(8):1545-1552. doi: 10.1016/j.drudis.2020.06.018. Epub 2020 Jun 20.

DOI:10.1016/j.drudis.2020.06.018
PMID:32574697
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7305909/
Abstract

We review the evolution of our clinical understanding of COVID-19, possible therapeutic targets, and prospects for COVID-19 management.

摘要

我们回顾了对 COVID-19 的临床认识的演变、可能的治疗靶点以及 COVID-19 管理的前景。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4fc/7305909/d3e2a5c1b862/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4fc/7305909/d3e2a5c1b862/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4fc/7305909/d3e2a5c1b862/gr1_lrg.jpg

相似文献

1
Current and future therapeutical approaches for COVID-19.当前和未来治疗 COVID-19 的方法。
Drug Discov Today. 2020 Aug;25(8):1545-1552. doi: 10.1016/j.drudis.2020.06.018. Epub 2020 Jun 20.
2
COVID-19: Small-Molecule Clinical Trials Landscape.新冠病毒病（COVID-19）：小分子药物临床试验全景
Curr Top Med Chem. 2020;20(18):1577-1580. doi: 10.2174/156802662018200703154334.
3
Responding to Covid-19 - A Once-in-a-Century Pandemic?应对新冠疫情——一场百年一遇的大流行病？
N Engl J Med. 2020 Apr 30;382(18):1677-1679. doi: 10.1056/NEJMp2003762. Epub 2020 Feb 28.
4
COVID-19 in the Eastern Mediterranean Region and Saudi Arabia: prevention and therapeutic strategies.中东地区和沙特阿拉伯的 COVID-19 疫情：预防和治疗策略。
Int J Antimicrob Agents. 2020 May;55(5):105968. doi: 10.1016/j.ijantimicag.2020.105968. Epub 2020 Apr 4.
5
Current development of COVID-19 diagnostics, vaccines and therapeutics.新型冠状病毒肺炎诊断、疫苗和治疗药物的最新进展。
Microbes Infect. 2020 Jul-Aug;22(6-7):231-235. doi: 10.1016/j.micinf.2020.05.001. Epub 2020 May 6.
6
COVID-19: The Need for Immunoprevention at Industrial Scale.新型冠状病毒肺炎：大规模免疫预防的必要性
Am J Trop Med Hyg. 2020 Jun;102(6):1151. doi: 10.4269/ajtmh.20-0239.
7
The Race to Develop a COVID-19 Vaccine.新冠疫苗研发竞赛。
Am J Nurs. 2020 Oct;120(10):14-15. doi: 10.1097/01.NAJ.0000718556.85319.00.
8
[SARS-CoV-2 protease: an excellent target to develop drugs against COVID-19].[严重急性呼吸综合征冠状病毒2蛋白酶：开发抗2019冠状病毒病药物的理想靶点]
Med Sci (Paris). 2020 Jun-Jul;36(6-7):555-558. doi: 10.1051/medsci/2020106. Epub 2020 Jun 19.
9
Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines: Setting Expectations Appropriately.严重急性呼吸综合征冠状病毒2疫苗：合理设定预期
Pediatr Infect Dis J. 2020 Jul;39(7):e123-e124. doi: 10.1097/INF.0000000000002741.
10
SARS-CoV-2: a time for clear and immediate action.严重急性呼吸综合征冠状病毒2：是采取明确且立即行动的时候了。
Lancet Infect Dis. 2020 May;20(5):531-532. doi: 10.1016/S1473-3099(20)30250-4. Epub 2020 Mar 31.

引用本文的文献

1
Current Insights and Molecular Docking Studies of the Drugs under Clinical Trial as RdRp Inhibitors in COVID-19 Treatment.在 COVID-19 治疗中作为 RdRp 抑制剂处于临床试验阶段的药物的最新研究进展和分子对接研究。
Curr Pharm Des. 2022;28(46):3677-3705. doi: 10.2174/1381612829666221107123841.
2
Recent advances in small-molecular therapeutics for COVID-19.新型冠状病毒肺炎小分子疗法的最新进展
Precis Clin Med. 2022 Sep 24;5(4):pbac024. doi: 10.1093/pcmedi/pbac024. eCollection 2022 Dec.
3
An Update on Pharmacological Relevance and Chemical Synthesis of Natural Products and Derivatives with Anti SARS-CoV-2 Activity.

本文引用的文献

1
A global treatments for coronaviruses including COVID-19.全球针对冠状病毒（包括 COVID-19）的治疗方法。
J Cell Physiol. 2020 Dec;235(12):9133-9142. doi: 10.1002/jcp.29785. Epub 2020 May 11.
2
Editorial: Nicotine and SARS-CoV-2: COVID-19 may be a disease of the nicotinic cholinergic system.社论：尼古丁与严重急性呼吸综合征冠状病毒2：2019冠状病毒病可能是一种烟碱能胆碱能系统疾病。
Toxicol Rep. 2020 Apr 30;7:658-663. doi: 10.1016/j.toxrep.2020.04.012. eCollection 2020.
3
Ongoing Clinical Trials for the Management of the COVID-19 Pandemic.正在进行的 COVID-19 大流行管理临床试验。
具有抗SARS-CoV-2活性的天然产物及其衍生物的药理相关性与化学合成进展
ChemistrySelect. 2021 Nov 15;6(42):11502-11527. doi: 10.1002/slct.202103301. Epub 2021 Nov 8.
4
Functionalized Dendrimer Platforms as a New Forefront Arsenal Targeting SARS-CoV-2: An Opportunity.功能化树枝状大分子平台作为靶向新型冠状病毒的前沿新武器库：一次机遇。
Pharmaceutics. 2021 Sep 18;13(9):1513. doi: 10.3390/pharmaceutics13091513.
5
Angiotensin-Converting Enzyme 2 in the Pathogenesis of Renal Abnormalities Observed in COVID-19 Patients.血管紧张素转换酶2在新冠病毒病患者肾脏异常发病机制中的作用
Front Physiol. 2021 Aug 23;12:700220. doi: 10.3389/fphys.2021.700220. eCollection 2021.
6
Factors associated with chemsex in Portugal during the COVID-19 pandemic.与 COVID-19 大流行期间葡萄牙的 Chemsex 相关的因素。
Rev Lat Am Enfermagem. 2021 Aug 30;29:e3474. doi: 10.1590/1518-8345.4975.3474. eCollection 2021.
7
The race to treat COVID-19: Potential therapeutic agents for the prevention and treatment of SARS-CoV-2.治疗 COVID-19 的竞赛：预防和治疗 SARS-CoV-2 的潜在治疗药物。
Eur J Med Chem. 2021 Mar 5;213:113157. doi: 10.1016/j.ejmech.2021.113157. Epub 2021 Jan 12.
8
Non-invasive intranasal administration route directly to the brain using dendrimer nanoplatforms: An opportunity to develop new CNS drugs.非侵入性鼻腔内给药途径直接进入大脑使用树枝状聚合物纳米平台：开发新的中枢神经系统药物的机会。
Eur J Med Chem. 2021 Jan 1;209:112905. doi: 10.1016/j.ejmech.2020.112905. Epub 2020 Oct 11.
9
Comparative docking studies to understand the binding affinity of nicotine with soluble ACE2 (sACE2)-SARS-CoV-2 complex over sACE2.通过比较对接研究来了解尼古丁与可溶性血管紧张素转换酶2（sACE2）-严重急性呼吸综合征冠状病毒2（SARS-CoV-2）复合物结合的亲和力，以及与sACE2结合亲和力的差异。
Toxicol Rep. 2020;7:1366-1372. doi: 10.1016/j.toxrep.2020.10.002. Epub 2020 Oct 8.
10
Azvudine (FNC): a promising clinical candidate for COVID-19 treatment.阿兹夫定（FNC）：一种有前景的用于治疗新冠肺炎的临床候选药物。
Signal Transduct Target Ther. 2020 Oct 10;5(1):236. doi: 10.1038/s41392-020-00351-z.
Trends Pharmacol Sci. 2020 Jun;41(6):363-382. doi: 10.1016/j.tips.2020.03.006. Epub 2020 Apr 9.
4
Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model.通过药物-靶点相互作用深度学习模型预测可能作用于新型冠状病毒（SARS-CoV-2）的市售抗病毒药物。
Comput Struct Biotechnol J. 2020 Mar 30;18:784-790. doi: 10.1016/j.csbj.2020.03.025. eCollection 2020.
5
COVID-19: immunopathology and its implications for therapy.新型冠状病毒肺炎：免疫病理学及其治疗意义。
Nat Rev Immunol. 2020 May;20(5):269-270. doi: 10.1038/s41577-020-0308-3.
6
Advance of promising targets and agents against COVID-19 in China.中国针对新型冠状病毒肺炎的有前景靶点和药物的进展
Drug Discov Today. 2020 May;25(5):810-812. doi: 10.1016/j.drudis.2020.02.011. Epub 2020 Mar 18.
7
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.洛匹那韦-利托那韦治疗成人重症 COVID-19 患者的临床试验。
N Engl J Med. 2020 May 7;382(19):1787-1799. doi: 10.1056/NEJMoa2001282. Epub 2020 Mar 18.
8
Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China.中国南京接触者中 24 例新冠肺炎无症状感染的临床特征。
Sci China Life Sci. 2020 May;63(5):706-711. doi: 10.1007/s11427-020-1661-4. Epub 2020 Mar 4.
9
Effective Chemicals against Novel Coronavirus (COVID-19) in China.中国针对新型冠状病毒（COVID-19）的有效化学品。
Curr Top Med Chem. 2020;20(8):603-605. doi: 10.2174/1568026620999200305145032.
10
Therapeutic options for the 2019 novel coronavirus (2019-nCoV).2019新型冠状病毒（2019-nCoV）的治疗选择。
Nat Rev Drug Discov. 2020 Mar;19(3):149-150. doi: 10.1038/d41573-020-00016-0.